Drug intelligence / Profile preview

ATSN-701

Development stage: Preclinical
Lead developer: Atsena Therapeutics
Modality: Gene Therapies
Administration: Ophthalmic

Overview

ATSN-701 is an undisclosed preclinical gene therapy candidate being developed by Atsena Therapeutics for the treatment of inherited retinal diseases. The program utilizes Atsena's proprietary adeno-associated virus (AAV) technology platform to deliver a functional copy of a therapeutic gene to the retina, aiming to prevent or reverse progressive vision loss. As of 2026, the specific target gene and indication remain undisclosed, and the program is in the discovery/preclinical stage.

Beyond the preview

Go deeper on ATSN-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATSN-701.

Explore the full profile